Company Announcements

Director/PDMR Shareholding

Source: RNS
RNS Number : 0219X
Belluscura PLC
19 July 2024
 

19 July 2024

 

BELLUSCURA PLC

("Belluscura" or the "Company")

 

PDMR Award of Options

 

Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that the Company has today granted unapproved share options ("Options") of 4.0 million ordinary shares of 1 penny each in the Company ("Ordinary Shares") to Simon Neicheril, Chief Financial Officer. 

 

The Options have been awarded upon the recommendation of the Company's Remuneration Committee.

 

The Options have an exercise price of 14.5 pence per share (being the closing mid-market price of the Ordinary Shares on 18 July 2024) and will expire 10 years from the date of grant.

 

The Options are subject to the following performance criteria; 2.0 million Options will vest when the price of the Ordinary Shares reaches 20p. The further 2.0 million Options will vest when the price of the Ordinary Shares reaches 25p.  Each Option is exercisable into one Ordinary Share.

 

Upon a change in control of the Company, or an Offer for the Company's entire Share Capital, or termination of Mr. Neicheril's employment contract as a good leaver, all remaining unvested Options will vest immediately.

 

 

For further information please contact:

 

Belluscura plc

Tel: +44 (0)20 3128 8100

Adam Reynolds, Chairman


Robert Rauker, Chief Executive Officer






SPARK Advisory Partners Limited - Nominated Adviser

Tel: +44 (0)20 3368 3550

Neil Baldwin / Jade Bayat






Dowgate Capital Limited - Broker

Tel: +44 (0)20 3903 7715

Russell Cook / Nicholas Chambers






MHP Group - Financial PR & Investor Relations

Tel: +44 (0)20 3128 8100

Katie Hunt / Matthew Taylor

email: Belluscura@mhpgroup.com



 

About Belluscura plc (https://belluscura.com/)

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.

 

 1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Simon Neicheril

2

Reason for notification

a)

Position / status

Chief Financial Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Belluscura plc

b)

LEI

213800BRJQZE56XBPW94

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of £0.01 each in Belluscura plc

ISIN: GB00BD3B8Z11

b)

Nature of the transaction

Grant of Options over Ordinary shares of £0.01 each

 

c)

Price(s) and volumes(s)

Price(s)

Volumes(s)

14.5p

4,000,000

 

 

 

 

 

d)

Aggregated information

n/a

e)

Date of the transaction

19 July 2024

f)

Place of the transaction

Outside a Trading Venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHRPMTTMTMBTLI